Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | HTR6 | P50406 | 11/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1747995 | 0.99 | HPGD (0.64) | HPGDSMN1; SMN2HTR6ALDH1A1MAPT | |
| SCHEMBL20242670 | 0.90 | HTR6 (0.57) | HPGDSMN1; SMN2HTR6MAPTMAPK1 | |
| SCHEMBL12528587 | 0.87 | HTR6 (0.58) | HPGDSMN1; SMN2HTR6ALDH1A1MAPT | |
| SCHEMBL1747990 | 0.87 | HTR6 (0.68) | HPGDSMN1; SMN2HTR6ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1748809 | 0.86 | HTR6 (0.67) | HPGDSMN1; SMN2HTR6ALDH1A1MAPT | |
| SCHEMBL20242549 | 0.86 | HTR6 (0.53) | HPGDSMN1; SMN2HTR6ALDH1A1MAPT | |
| SCHEMBL5021118 | 0.86 | HTR6 (0.53) | HPGDSMN1; SMN2HTR6ALDH1A1MAPT | |
| SCHEMBL1748852 | 0.85 | HTR6 (0.64) | HPGDSMN1; SMN2HTR6CNR1 | |
| SCHEMBL12527143 | 0.83 | HTR6 (0.64) | HPGDSMN1; SMN2HTR6ALDH1A1MAPT | |
| SCHEMBL1748556 | 0.81 | HTR6 (0.69) | HPGDSMN1; SMN2HTR6CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604021-B2 | Substituted arylamine compounds and methods of treatment | BECKER OREN (IL) | 2013-12-10 | — | — | US | claimed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | claimed |
| EP-2037925-B1 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS | GALENEA CORP (US) | 2012-02-01 | — | — | EP | claimed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | claimed |
| US-20100152141-A1 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS | EPIX DELAWARE, INC (US) | 2010-06-17 | — | — | US | claimed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | claimed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| US-20100152141-A1 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS | EPIX DELAWARE, INC (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2037925-A1 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS | Epix Delaware, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2008002539-A1 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS | EPIX DELAWARE, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152141-A1 | COMBINATIONS COMPRISING 5HT6 MODULATORS AND CHOLINESTERASE INHIBITORS | HTR6, HTR3B, HTR1B | HPGD 1316/4885SMN1; SMN2 2720/4885HTR6 1/4885 |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | HPGD 2326/4885SMN1; SMN2 3858/4885HTR6 1/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | HPGD 2326/4885SMN1; SMN2 3858/4885HTR6 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.